STEVE PAKOLA
CIK 1700659 · Chief Medical Officer · last filed 2026-08-04
STEVE PAKOLA is a Chief Medical Officer who has filed 25 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing shows the insider had shares withheld for taxes covering $72.4K of RGNX on Aug 4, 2026. Across all open-market trades the lifetime net is −$1.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.32M
2
25
-$1.73M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RGNX | Chief Medical Officer | 205,541 | $11.28 | $2.32M | -$1.73M | 18 | 2026-08-04 |
| Whitehawk Therapeutics, Inc. (ARPO) Delisted | Chief Medical Officer | — | $33.00 | — | $0 | 1 | 2019-02-20 |
Recent Filings
25 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-04 | RGNX | Tax (F) | −7,468 | -$72.4K | EDGAR |
| 2026-07-06 | RGNX | Mixed | — | -$12.5K | EDGAR |
| 2026-07-01 | RGNX | Notice (144) | −43,206 | -$517.6K | EDGAR |
| 2026-07-01 | RGNX | Mixed | −19,608 | -$400.1K | EDGAR |
| 2026-05-13 | RGNX | Sell (S) | −15,309 | -$168.7K | EDGAR |
| 2026-05-11 | RGNX | Notice (144) | −34,917 | -$368.4K | EDGAR |
| 2026-03-12 | RGNX | Sell (S) | −5,124 | -$53.0K | EDGAR |
| 2026-03-10 | RGNX | Notice (144) | −5,124 | -$53.2K | EDGAR |
| 2026-02-03 | RGNX | Tax (F) | −5,267 | -$58.8K | EDGAR |
| 2026-01-08 | RGNX | Grant (A) | +65,847 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.